1. Groff WA, Ellin R and Skalsky RL (1977): Quantitative assay of physostigmine in human whole blood. J. Pharmaceut. Sci. 66:389–391.
2. Marquis JK (1990): Pharmacological significance of acetylcholinesterase inhibition by tetrahydroaminoacridine. Biochem. Pharmacol. 40:1071–1076.
3. Sherman KA and Messamore E (1988) Blood cholinesterase inhibition as a guide to the efficacy of putative therapies for Alzheimer’s dementia: comparison of tacrine and physostigmine. In: Current Research in Alzheimer Therapy: Cholinesterase Inhibitors, Giacobini E and Becker R, eds. New York: Taylor and Francis Intl. Publ., pp. 73–86.
4. Sherman KA and Messamore E (1989): Cholinesterase inhibitor therapy for Alzheimer dementia: what do animal models tell us? Prog. Clin. Biol. Res. 317:1209–1222.
5. Sherman KA, Harms KF and Doyle EA (1991): Measuring efficacy of reversible cholinesterase inhibitors for Alzheimer’s. In: Basic, Clinical and Therapeutic Aspects of Alzheimer’s and Parkinson’s Diseases, Vol. 2, Nagatsu T, Fisher A and Yoshida M, eds. NY: Plenum Press, pp. 477–484.